参考文献/References:
[1] Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency[J].Diabetes Care, 2013,36(5):1067-1073.
[2] Mcgill JB, Sloan L, Newman J, et al. Long-Term efficacy and safety of linagliptin in patients with type2 diabetes and severe renal impairment[J].Diabetes Care, 2013,36(2):237-244.
[3] Haidinger M, Werzowa J, Voigt HC, et al. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation[J].Trials, 2010, 11: 91.
[4] Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors[J]. Ther Adv Endocrinol Metab, 2013, 4: 95-105.
[5] Haluzík M, Frolík J, Rychlík I. Renal effects of DPP-4 inhibitors: A focus on microalbuminuria[J]. Int J Endocrinol, 2013, 2013: 895102.
[6] Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes[J]. Endocr J,2011,58(1):69-73.
[7] Harashima SI, Ogura M, Tanaka D, et al. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes[J].Int J Clin Pract, 2012,66(5):465-476.
[8] Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction[J].Diabetes Care, 2013,36(11):3460-3468.
[9] Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes(ZDF rat). Mediators Inflamm, 2010, 2010: 592760.
[10] Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis[J].Circulation, 2011,124(21):2338-2349.
[11] Akarte AS, Srinivasan BP, Gandhi S, et al. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats[J].Eur J Pharm Sci, 2012,47(2):456-463.
[12] Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients[J].Metabolism,2013,62(3):347-351.
[13] Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-Ⅳ inhibition[J].Diabetes Care, 2012,35(10):2076-2082.
[14] Shah Z, Pineda C, Kampfrath T, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways[J].Vascul Pharmacol, 2011,55(1-3):2-9.
[15] Xiao-Yun X, Zhao-Hui M, Ke C, et al. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF Generation[J].Med Sci Monit, 2011,17(2):BR35-BR41.
[16] Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury[J].Am J Physiol Renal Physiol, 2012,303(5):F681-F688.
[17] Pacheco BP, Crajoinas RO, Couto GK, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats[J].J Hypertens, 2011,29(3):520-528.
[18] Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice[J].Am J Physiol Renal Physiol, 2012,303(7):F963-F971.
[19] Derosa G,Ragonesi PD, Fogari E,et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol,2014,28(2):221-229.
[20] Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis[J].Adv Ther, 2012,29(1):14-25.
相似文献/References:
[1]王思倩,吴锦丹.肠促胰素对1型糖尿病患者血糖及胰岛功能的影响[J].国际内分泌代谢杂志,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
Wang Siqian,Wu Jindan..Effects of incretin on blood glucose and islet function in type 1 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(05):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
[2]丁静雅,梁雅灵,徐勇,等.糖尿病正常白蛋白尿而肾功能不全的研究进展[J].国际内分泌代谢杂志,2016,36(05):349.[doi:10.3760/cma.j.issn.1673-4157.2016.05.17]
Ding Jingya,Liang Yaling,Xu Yong,et al.Update of normoalbuminuric renal insufficiency in diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(05):349.[doi:10.3760/cma.j.issn.1673-4157.2016.05.17]